Peptide Research Library

Dihexa

Main evidence: Manufacturer information. Updated 2026-10-30.

What research and users report, not a recommendation or medical advice. Many of these products are not approved for human use. Ask your doctor. Packs report what sources say, each with its evidence label. A claim labelled community, educator, manufacturer or animal has not been validated in humans.

Summary

This pack reports source-labelled product-page information and limited general Australian regulatory context without making a Dihexa-specific Australian legal-status determination.

Australian legal status

According to the official source tga-peptides, peptide products are regulated as therapeutic goods in Australia. It explains that unapproved peptide products are goods not included in the ARTG and that an RUO disclaimer does not itself make supply lawful. This general guidance does not identify Dihexa or establish a Dihexa-specific Australian legal status, so none is stated in this pack.

What the sources say

• What it is — The manufacturer source describes Dihexa as an angiotensin IV-derived peptidomimetic, also called PNB-0408. This is manufacturer information and has not been validated in humans. (Manufacturer information; Peptigrity Dihexa product page, 2026-08-03)
• Approval or study status — The manufacturer source describes Dihexa as investigational and unapproved, with preclinical evidence and no controlled human efficacy trials. This is manufacturer information and has not been validated in humans. (Manufacturer information; Peptigrity Dihexa product page, 2026-08-03)
• The manufacturer source describes Dihexa research as preclinical, including cell-based, ex vivo hippocampal-slice, and animal studies. This is manufacturer information and has not been validated in humans. (Manufacturer information; Peptigrity Dihexa product page, 2026-08-03)
• The manufacturer source describes proposed potentiation of HGF/c-Met signalling and hippocampal synapse formation in preclinical models. This is manufacturer information and has not been validated in humans. (Manufacturer information; Peptigrity Dihexa product page, 2026-08-03)
• The manufacturer source reports no established human safety profile and identifies HGF/c-Met as a pathway implicated in cancer biology. This is manufacturer information and has not been validated in humans. (Manufacturer information; Peptigrity Dihexa product page, 2026-08-03)

Sources

1. Peptigrity Dihexa product page (2026-08-03)

Dosing, stacking and protocol details are not published here.